Along these lines, similar levels of anti-MBP from oligodendrocyte-derived EVs were found in the MS-naïve patient group (12.46 ± 6.10 ng/mL) compared with the MS-treated group (13.43 ± 5.82 ng/mL, p=0.51). This evidence concerns the gene MBP and myeloid sarcoma.